Atea Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Atea Pharmaceuticals

06/05/2023 03:11

* Atea Pharmaceuticals Inc  AVIR.OQ   AVIR.O  is expected
to show
no change in quarterly revenue when it reports  results on May
8. 
    * 
    * ​Refinitiv's mean analyst estimate for Atea
Pharmaceuticals Inc
is for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $4​, above​ its last closing price
of $3.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.44       -0.45      -0.41     Beat    8.9
 Sep. 30 2022  -0.41       -0.44      -0.10     Beat    77.4
 Jun. 30 2022  -0.53       -0.52      -0.38     Beat    27.4​
 Mar. 31 2022  -0.56       -0.58      -0.51     Beat    12.4
 ​​Dec.        -0.01       0.17       1.34      Beat    704
 31 2021                                                
 Sep. 30 2021  -0.12       -0.05      -0.34     Missed  -547.6
                                                        ​
 Jun. 30 2021  -0.10       0.01       0.02      Beat    300
 Mar. 31 2021  -0.10       -0.05      0.34      Beat    718.2
 This summary was machine generated May 6 at 02:11 GMT.  All
figures in US dollars  unless otherwise stated